"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
- Clinician Information:
Hepflush Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Hepflush-10 (heparin lock flush solution) is an anticoagulant used to maintain patency of an indwelling venipuncture device designed for intermittent injection or infusion therapy or blood sampling. Heparin lock flush solution may be used following initial placement of the device in the vein, after each injection of a medication or after withdrawal of blood for laboratory tests. Hepflush-10 is not to be used for anticoagulant therapy. Common side effects include bleeding.
Dose of Hepflush-10 is determined by a physician. Hepflush-10 may interact with acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine, digitalis, tetracyclines, nicotine, or antihistamines. Tell your doctor all medications and supplements you use. During pregnancy, Hepflush-10 should be used only if prescribed. This drug does not pass into breast milk. Consult your doctor before breastfeeding.
Our Hepflush-10 (heparin lock flush solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Hepflush FDA Prescribing Information: Side Effects
Hemorrhage is the chief complication that may result from heparin use (see WARNINGS). An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug (see OVERDOSAGE).
Thrombocytopenia, Heparin-induced Throm-bocytopenia (HIT) and Heparin-induced Throm-bocytopenia and Thrombosis (HITT) and Delayed Onset of HIT and HITT
Local irritation and erythema have been reported with the use of heparin lock flush solution.
Generalized hypersensitivity reactions have been reported, with chills, fever and urticaria as the most usual manifestations, and asthma, rhinitis, lacrima-tion, headache, nausea and vomiting, and ana-phylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar side of the feet, may occur.
Thrombocytopenia has been reported to occur in patients receiving heparin, with a reported incidence of 0 to 30%. While often mild and of no obvious clinical significance, such thrombocytopenia can be accompanied by severe thromboembolic complications such as skin necrosis, gangrene of the extremities that may lead to amputation, myocar-dial infarction, pulmonary embolism, stroke, and possibly death (see WARNINGS, PRECAUTIONS).
Certain episodes of painful, ischemic and cyanosed limbs have in the past been attributed to allergic vasospastic reactions. Whether these are in fact identical to the thrombocytopenia-associated complications remains to be determined.
Read the entire FDA prescribing information for Hepflush (Heparin Lock Flush Solution) »
Additional Hepflush 10 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.